IMARC Group has recently released a new research study titled “United States Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region, 2026-2034,” offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

United States Cancer Biomarkers Market Size, Growth, and Forecast (2026-2034)

The united states cancer biomarkers market size reached USD 8.6 Billion in 2025 and is projected to reach USD 22.4 Billion by 2034, growing at a CAGR of 10.90% during 2026-2034. The shift toward precision medicine and personalized therapies, which raises demand for biomarkers that identify the most effective treatment for each patient, is the primary factor driving the united states cancer biomarkers market.

Cancer biomarkers are molecules or genetic alterations that can be objectively measured and indicate the presence of cancer or its potential to develop. They can be found in blood, tissue, or urine, and they help identify cancer types, assess disease stage, predict treatment response, and monitor recurrence.

Advances in molecular biology and genomics have led to many new biomarkers that guide targeted treatment. Within this landscape, the us prostate cancer biomarkers market is an important area, as tests for risk assessment, prognosis, and therapy selection become more common in prostate cancer care.

Explore Growth Opportunities in the United States Cancer Biomarkers Market - Grab Your Sample Report for Evaluation: https://www.imarcgroup.com/united-states-cancer-biomarkers-market/requestsample

Key Trends Driving the United States Cancer Biomarkers Market

• Advances in genomic and proteomic technologies: Progress in genomics and proteomics has helped identify novel biomarkers, widening the set of available diagnostic and prognostic tools. Collaboration among academic institutions, research organizations, and pharmaceutical companies is speeding biomarker discovery across the united states cancer biomarkers market.
• Rising cancer incidence and demand for early detection: The growing incidence of cancer in the United States is increasing the need for precise and early detection methods. Biomarkers enable earlier diagnosis and risk assessment, which supports better treatment planning, including in the us prostate cancer biomarkers market.
• Growing adoption of liquid biopsy and personalized medicine: Liquid biopsy and other non-invasive diagnostic methods are gaining traction because they reduce the need for invasive procedures. At the same time, personalized medicine is driving R&D into biomarkers tied to individual patient profiles, improving diagnostic accuracy and enabling targeted therapy.

United States Cancer Biomarkers Market Report Segmentation:

The United States Cancer Biomarkers Market report provides a detailed segmentation analysis to help businesses identify key growth segments and evolving industry dynamics. The market is categorized based on profiling technology, biomolecule, cancer type, application, and end user, offering comprehensive insights across the united states cancer biomarkers market.

Profiling Technology Insights:

• Omic Technologies: Omic technologies, including genomics and proteomics, underpin biomarker discovery and comprehensive tumor profiling.
• Imaging Technologies: Imaging technologies support non-invasive detection and monitoring of cancer-related changes.
• Immunoassays: Immunoassays measure protein biomarkers in blood and other fluids and are widely used in routine testing.
• Cytogenetics: Cytogenetics examines chromosomal changes in cancer cells to support diagnosis and prognosis.

Biomolecule Insights:

• Genetic Biomarkers: Genetic biomarkers identify mutations and gene alterations that guide diagnosis and targeted therapy selection.
• Protein Biomarkers: Protein biomarkers are measured in blood, urine, or tissue and are widely used for screening, monitoring, and risk assessment.
• Glyco-Biomarkers: Glyco-biomarkers detect changes in sugar-modified molecules associated with cancer, an emerging area of research.

Cancer Type Insights:

• Breast Cancer: Breast cancer biomarkers guide diagnosis, prognosis, and the choice of targeted therapies.
• Lung Cancer: Lung cancer biomarkers help identify actionable mutations that inform treatment decisions.
• Colorectal Cancer: Colorectal cancer biomarkers support early detection, prognosis, and therapy selection.
• Prostate Cancer: Prostate cancer is a key segment, with biomarkers used for risk assessment, biopsy decisions, and therapy guidance, which keeps the us prostate cancer biomarkers market in focus.
• Stomach Cancer: Stomach cancer biomarkers aid in diagnosis and in matching patients to appropriate treatment.
• Others: Other cancer types continue to benefit from expanding biomarker research and clinical adoption.

Application Insights:

• Diagnostics: Diagnostic applications use biomarkers to detect cancer and identify its specific type.
• Prognostics: Prognostic applications predict disease course and likely outcomes to guide care intensity.
• Risk Assessment: Risk assessment applications estimate the likelihood of developing or progressing to cancer.
• Drug Discovery and Development: Biomarkers help pharmaceutical companies select patients, track response, and speed up clinical development.
• Others: Other applications include treatment monitoring and detection of recurrence.

End User Insights:

• Hospitals: Hospitals are major users, integrating biomarker testing into cancer diagnosis and treatment pathways.
• Academic and Research Institutions: Academic and research institutions drive biomarker discovery and validation.
• Ambulatory Surgical Centers: Ambulatory surgical centers use biomarker testing to support outpatient cancer care.
• Diagnostic Laboratories: Diagnostic laboratories perform much of the specialized biomarker testing used across oncology.
• Others: Other end users include specialty clinics and pharmaceutical organizations.

Regional Insights:

• Northeast: The Northeast contributes to the united states cancer biomarkers market through its leading academic medical centers and research institutions.
• Midwest: The Midwest supports demand through its large hospital systems and cancer research centers.
• South: The South is a significant region, with a large patient population and expanding healthcare infrastructure.
• West: The West benefits from its concentration of biotechnology and genomics companies.

United States Cancer Biomarkers Market: Recent News and Developments

• December 2025: Cleveland Diagnostics received FDA premarket approval for its IsoPSA in vitro diagnostic kit, a blood-based test that helps decide on prostate biopsy for men aged 50 and older with elevated PSA levels. The approval is a notable milestone for the us prostate cancer biomarkers market.
• June 2026: Foundation Medicine announced FDA approval of FoundationOne® CDx and FoundationOne® Liquid CDx as companion diagnostics to identify patients with HRR gene-mutated metastatic castration-resistant prostate cancer who may be eligible for TALZENNA® plus XTANDI®.

Challenges Impacting the United States Cancer Biomarkers Market

High costs of advanced biomarker tests and uneven insurance coverage can limit patient access. Complex regulatory pathways and the need for rigorous clinical validation also lengthen the time it takes for new tests to reach the market.

Variation in test standardization, data interpretation challenges, and limited awareness in some care settings further slow adoption across the united states cancer biomarkers market.

Investment Opportunities in the United States Cancer Biomarkers Market

The united states cancer biomarkers market presents compelling investment opportunities supported by its projected growth from USD 8.6 Billion in 2025 to USD 22.4 Billion by 2034. Liquid biopsy, companion diagnostics, and multi-cancer detection tools offer particularly strong potential.

AI-enabled analysis, partnerships with pharmaceutical developers, and targeted growth in the us prostate cancer biomarkers market also create openings. Companies that combine clinically validated tests with broad payer and provider access can build lasting competitive positions.

Outlook of the United States Cancer Biomarkers Market (2026-2034)

The outlook for the united states cancer biomarkers market is positive, supported by precision medicine, rising cancer incidence, and continuous technological innovation. The market is projected to grow from USD 8.6 Billion in 2025 to USD 22.4 Billion by 2034 at a CAGR of 10.90%.

Wider use of liquid biopsy, next-generation sequencing, companion diagnostics, and non-invasive testing will be the defining trends shaping the united states cancer biomarkers market, including the us prostate cancer biomarkers market, through 2034.

Key Players in the United States Cancer Biomarkers Market

The united states cancer biomarkers market is served by a mix of genomic profiling companies, diagnostics firms, and life science providers competing on the basis of test accuracy, clinical validation, and therapy partnerships.

• Foundation Medicine: A leader in comprehensive genomic profiling, Foundation Medicine offers FDA-approved tissue and blood-based tests, with over 100 approved companion diagnostic indications in total and nine for prostate cancer, according to the company.
• Myriad Genetics: Based in Salt Lake City, Utah, Myriad Genetics is a molecular diagnostics company whose Prolaris® test supports genomic risk assessment and treatment planning in prostate cancer.

Frequently Asked Questions (FAQs): United States Cancer Biomarkers Market

1. What is the current United States cancer biomarkers market size?

The united states cancer biomarkers market size reached USD 8.6 Billion in 2025 and is projected to reach USD 22.4 Billion by 2034, growing at a CAGR of 10.90% during 2026-2034.

2. What are cancer biomarkers?

Cancer biomarkers are molecules or genetic alterations that can be objectively measured and indicate the presence of cancer or its potential to develop, helping with diagnosis, prognosis, and treatment decisions.

3. What are the key drivers of the United States cancer biomarkers market?

Key drivers include the shift toward precision medicine, advances in genomic and proteomic technologies, rising cancer incidence, and growing adoption of liquid biopsy and non-invasive testing.

4. What is the US prostate cancer biomarkers market?

The us prostate cancer biomarkers market covers tests that measure molecular and protein markers to assess risk, guide biopsy decisions, and select therapies for prostate cancer, and it forms a key part of the broader cancer biomarkers landscape.

5. Who are the key players in the United States cancer biomarkers market?

Key players in the united states cancer biomarkers market include Foundation Medicine and Myriad Genetics, alongside other genomic profiling companies and diagnostics providers serving hospitals and laboratories.

Author IMARC Group 

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

United States: +1-201971-6302